Penumbra, Inc. (NYSE:PEN) Stock Holdings Lifted by Jones Financial Companies Lllp

Jones Financial Companies Lllp raised its position in Penumbra, Inc. (NYSE:PEN) by 25.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 375 shares of the company’s stock after purchasing an additional 75 shares during the quarter. Jones Financial Companies Lllp’s holdings in Penumbra were worth $89,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Janus Henderson Group PLC boosted its stake in shares of Penumbra by 128.1% during the 3rd quarter. Janus Henderson Group PLC now owns 668,873 shares of the company’s stock worth $129,967,000 after acquiring an additional 375,684 shares in the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of Penumbra by 3,832.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 368,298 shares of the company’s stock worth $71,564,000 after acquiring an additional 358,932 shares in the last quarter. Champlain Investment Partners LLC boosted its stake in shares of Penumbra by 20.6% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,547,972 shares of the company’s stock worth $300,786,000 after acquiring an additional 264,122 shares in the last quarter. Massachusetts Financial Services Co. MA bought a new stake in shares of Penumbra during the 3rd quarter worth about $31,965,000. Finally, Braidwell LP boosted its stake in shares of Penumbra by 70.0% during the 3rd quarter. Braidwell LP now owns 361,428 shares of the company’s stock worth $70,229,000 after acquiring an additional 148,834 shares in the last quarter. Hedge funds and other institutional investors own 88.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Piper Sandler reiterated an “overweight” rating and set a $330.00 price target (up previously from $250.00) on shares of Penumbra in a research note on Wednesday, February 19th. Wells Fargo & Company upped their price target on Penumbra from $275.00 to $305.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 19th. Needham & Company LLC reiterated a “hold” rating on shares of Penumbra in a research note on Wednesday, February 19th. JPMorgan Chase & Co. boosted their price objective on Penumbra from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 19th. Finally, Robert W. Baird boosted their price objective on Penumbra from $305.00 to $328.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 19th. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Penumbra presently has a consensus rating of “Moderate Buy” and a consensus target price of $294.47.

Insider Transactions at Penumbra

In other news, CFO Maggie Yuen sold 2,000 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $286.00, for a total value of $572,000.00. Following the completion of the transaction, the chief financial officer now directly owns 15,243 shares of the company’s stock, valued at approximately $4,359,498. This represents a 11.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Harpreet Grewal sold 167 shares of the stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $241.28, for a total value of $40,293.76. Following the sale, the director now owns 8,530 shares in the company, valued at approximately $2,058,118.40. This trade represents a 1.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 79,918 shares of company stock valued at $22,054,293. Corporate insiders own 5.00% of the company’s stock.

Penumbra Trading Up 4.9 %

Penumbra stock opened at $273.51 on Monday. The business has a 50 day moving average price of $269.89 and a two-hundred day moving average price of $237.89. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02. The stock has a market cap of $10.53 billion, a price-to-earnings ratio of 804.45, a price-to-earnings-growth ratio of 2.83 and a beta of 0.51. Penumbra, Inc. has a 12 month low of $148.00 and a 12 month high of $310.00.

Penumbra (NYSE:PEN) last posted its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.88 by $0.09. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The firm had revenue of $315.52 million during the quarter, compared to analysts’ expectations of $311.63 million. As a group, equities analysts forecast that Penumbra, Inc. will post 3.67 EPS for the current year.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.